Novo nordisk will stop the once-weekly injectable semaglutide kidney outcomes trial, flow, based on interim analysis

Novo nordisk will stop the once-weekly injectable semaglutide kidney outcomes trial, flow, based on interim analysis bagsvÆrd, denmark, 10 october 2023 – novo nordisk today announced the decision to stop the kidney outcomes trial flow (effect of semaglutide versus placebo on the progression of renal impairment in people with type 2 diabetes and chronic kidney disease). the decision to stop the trial is based on a recommendation from the independent data monitoring committee (dmc) concluding that the results from an interim analysis met certain pre-specified criteria for stopping the trial early for efficacy.
NVO Ratings Summary
NVO Quant Ranking